JP2022017221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022017221A5 JP2022017221A5 JP2021145986A JP2021145986A JP2022017221A5 JP 2022017221 A5 JP2022017221 A5 JP 2022017221A5 JP 2021145986 A JP2021145986 A JP 2021145986A JP 2021145986 A JP2021145986 A JP 2021145986A JP 2022017221 A5 JP2022017221 A5 JP 2022017221A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- compound according
- acceptable salt
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 110
- 150000001875 compounds Chemical class 0.000 claims 101
- 150000003839 salts Chemical class 0.000 claims 88
- 125000005843 halogen group Chemical group 0.000 claims 40
- 125000003118 aryl group Chemical group 0.000 claims 32
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 31
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 26
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 23
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 22
- 229910052799 carbon Inorganic materials 0.000 claims 21
- 125000004432 carbon atom Chemical group C* 0.000 claims 19
- 125000001424 substituent group Chemical group 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 claims 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 5
- 125000006193 alkinyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- -1 SCH 3 Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101000735473 Homo sapiens Protein mono-ADP-ribosyltransferase TIPARP Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100034905 Protein mono-ADP-ribosyltransferase TIPARP Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664544P | 2018-04-30 | 2018-04-30 | |
| US62/664,544 | 2018-04-30 | ||
| PCT/US2019/029582 WO2019212937A1 (en) | 2018-04-30 | 2019-04-29 | Pyridazinones as parp7 inhibitors |
| JP2020560916A JP6942896B2 (ja) | 2018-04-30 | 2019-04-29 | Ｐａｒｐ７阻害剤としてのピリダジノン |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560916A Division JP6942896B2 (ja) | 2018-04-30 | 2019-04-29 | Ｐａｒｐ７阻害剤としてのピリダジノン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022017221A JP2022017221A (ja) | 2022-01-25 |
| JP2022017221A5 true JP2022017221A5 (enExample) | 2022-06-10 |
| JP7518049B2 JP7518049B2 (ja) | 2024-07-17 |
Family
ID=66476851
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560916A Active JP6942896B2 (ja) | 2018-04-30 | 2019-04-29 | Ｐａｒｐ７阻害剤としてのピリダジノン |
| JP2021145986A Active JP7518049B2 (ja) | 2018-04-30 | 2021-09-08 | Ｐａｒｐ７阻害剤としてのピリダジノン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560916A Active JP6942896B2 (ja) | 2018-04-30 | 2019-04-29 | Ｐａｒｐ７阻害剤としてのピリダジノン |
Country Status (36)
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020022006A2 (pt) * | 2018-04-30 | 2021-01-26 | Ribon Therapeutics Inc. | piridazinonas como inibidores de parp7 |
| US11293927B2 (en) | 2018-04-30 | 2022-04-05 | Ribon Therapeutics, Inc. | Screening methods for PARP modulators |
| WO2019241131A1 (en) | 2018-06-11 | 2019-12-19 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine m1 receptor antagonists |
| CN119112895A (zh) | 2018-09-04 | 2024-12-13 | 康蒂内乌姆医疗公司 | 毒蕈碱性乙酰胆碱m1受体拮抗剂 |
| MX2021011316A (es) * | 2019-03-20 | 2021-10-13 | Goldfinch Bio Inc | Piridazinonas y metodos de uso de estas. |
| WO2020223229A1 (en) * | 2019-04-29 | 2020-11-05 | Ribon Therapeutics, Inc. | Solid forms of a parp7 inhibitor |
| IL326597A (en) * | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic acetylcholine m1 receptor antagonists |
| WO2021087018A1 (en) * | 2019-10-30 | 2021-05-06 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| TWI902715B (zh) * | 2019-10-30 | 2025-11-01 | 美商律幫治療股份有限公司 | 作為ｐａｒｐ７抑制劑的嗒酮 |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| JP7842698B2 (ja) * | 2020-04-23 | 2026-04-08 | オプナ バイオ ソシエテ アノニム | Ｃｄ７３調節のための化合物及び方法並びにそれらの表示 |
| US20230219942A1 (en) * | 2020-06-09 | 2023-07-13 | Relive Therapeutics Inc. | Compounds comprising a three ring core as pd-1/pd-l1 blockers |
| KR102873922B1 (ko) * | 2020-07-03 | 2025-10-20 | 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 | 헤테로고리 화합물 및 이의 용도 |
| CN116157396B (zh) * | 2020-11-27 | 2025-07-18 | 康百达（四川）生物医药科技有限公司 | 哒嗪酮衍生物及其在医药上的应用 |
| JP7623826B2 (ja) * | 2020-12-18 | 2025-01-29 | 株式会社 資生堂 | Ｔｉｐａｒｐ産生促進剤 |
| WO2022156708A1 (en) * | 2021-01-20 | 2022-07-28 | Jacobio Pharmaceuticals Co., Ltd. | Parp7 enzyme inhibitor |
| US20240166664A1 (en) * | 2021-02-03 | 2024-05-23 | Shanghai Apeiron Therapeutics Company Limited | Triheterocyclic compound, preparation method therefor, and application thereof |
| US20240317755A1 (en) * | 2021-02-07 | 2024-09-26 | Wuhan Ll Science And Technology Development Co., Ltd. | Heterocyclic compound, and intermediate thereof, preparation method therefor and use thereof |
| EP4291560A4 (en) * | 2021-02-09 | 2025-01-15 | Jacobio Pharmaceuticals Co., Ltd. | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS |
| EP4294399A1 (en) | 2021-02-16 | 2023-12-27 | Ribon Therapeutics Inc. | Dosage regimens for parp7 inhibitors |
| CN115028648B (zh) * | 2021-03-03 | 2024-08-30 | 武汉誉祥医药科技有限公司 | 三并环化合物及其药物组合物和应用 |
| WO2022188889A1 (zh) * | 2021-03-12 | 2022-09-15 | 杭州英创医药科技有限公司 | 作为parp7抑制剂的化合物 |
| WO2022194122A1 (zh) * | 2021-03-16 | 2022-09-22 | 上海翰森生物医药科技有限公司 | 含氮杂环的多环化合物及其制备方法和应用 |
| GB202114315D0 (en) * | 2021-10-06 | 2021-11-17 | Duke Street Bio Ltd | Pharmaceutical compound |
| MX2023011378A (es) | 2021-03-31 | 2023-10-06 | Duke Street Bio Ltd | Compuesto farmaceutico. |
| WO2022223022A1 (zh) * | 2021-04-23 | 2022-10-27 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| CN117279917A (zh) * | 2021-05-21 | 2023-12-22 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
| WO2022247839A1 (zh) * | 2021-05-25 | 2022-12-01 | 山东轩竹医药科技有限公司 | Parp7抑制剂 |
| CN115477640A (zh) * | 2021-05-31 | 2022-12-16 | 由理生物医药（上海）有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
| WO2023001247A1 (zh) * | 2021-07-21 | 2023-01-26 | 南京明德新药研发有限公司 | 哒嗪酮类化合物 |
| WO2023001296A1 (zh) * | 2021-07-23 | 2023-01-26 | 武汉人福创新药物研发中心有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
| WO2023011629A1 (zh) * | 2021-08-06 | 2023-02-09 | 成都百裕制药股份有限公司 | 吡咯烷酮衍生物及其在医药上的应用 |
| WO2023020479A1 (zh) * | 2021-08-16 | 2023-02-23 | 重庆华森制药股份有限公司 | Parp7抑制剂及其应用 |
| CN117897380A (zh) * | 2021-08-17 | 2024-04-16 | 益方生物科技(上海)股份有限公司 | 哒嗪酮或吡啶酮化合物、其制备方法和用途 |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CN115745971B (zh) * | 2021-12-20 | 2024-07-30 | 北京华森英诺生物科技有限公司 | Parp7抑制剂及其应用 |
| CN116375688B (zh) * | 2021-12-23 | 2025-04-11 | 中国药科大学 | 哒嗪酮类化合物及其制备方法、药物组合物和应用 |
| CN116444497B (zh) * | 2022-01-14 | 2025-06-24 | 如东凌达生物医药科技有限公司 | 一类哒嗪酮类化合物、制备及其应用 |
| WO2023143236A1 (zh) * | 2022-01-26 | 2023-08-03 | 中国药科大学 | 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用 |
| CN116535395B (zh) * | 2022-01-26 | 2024-07-09 | 中国药科大学 | 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用 |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| WO2023185073A1 (zh) * | 2022-04-01 | 2023-10-05 | 诺沃斯达药业(上海)有限公司 | Parp7抑制剂及其用途 |
| TW202346294A (zh) * | 2022-04-21 | 2023-12-01 | 大陸商四川海思科製藥有限公司 | 吡嗪酮衍生物及其在醫藥上的應用 |
| WO2024032410A1 (zh) * | 2022-08-09 | 2024-02-15 | 成都百裕制药股份有限公司 | 哌嗪类化合物和pd-1抑制剂或pd-l1抑制剂的组合物以及其治疗肿瘤的用途 |
| CN117586263B (zh) * | 2022-08-09 | 2026-04-10 | 康百达（四川）生物医药科技有限公司 | 哌嗪衍生物及其在医药上的应用 |
| EP4570249A4 (en) * | 2022-08-09 | 2026-07-22 | Kangbaida Sichuan Biotechnology Co Ltd | USE OF A PIPERAZINE COMPOUND IN COMBINATION WITH RADIOTHERAPY FOR THE TREATMENT OF A TUMOR |
| TW202416984A (zh) * | 2022-08-17 | 2024-05-01 | 大陸商北京加科思新藥研發有限公司 | 化合物i或其鹽的固體形式 |
| GB202213819D0 (en) | 2022-09-22 | 2022-11-09 | Duke Street Bio Ltd | Pharmaceutical compound |
| CN115490671B (zh) * | 2022-10-21 | 2024-05-14 | 水木未来(北京)科技有限公司 | Parp7抑制剂及其制备方法 |
| CN117551080A (zh) * | 2022-11-11 | 2024-02-13 | 杭州师范大学 | 一种靶向降解parp7的protac化合物及其制备方法与应用 |
| TWI879228B (zh) * | 2022-11-14 | 2025-04-01 | 康百達（四川）生物醫藥科技有限公司 | 取代的哌衍生物的晶型及其製備方法、藥物組合物和製藥用途 |
| GB202217888D0 (en) | 2022-11-29 | 2023-01-11 | Duke Street Bio Ltd | Pharmaceutical compound |
| TW202430518A (zh) * | 2023-01-06 | 2024-08-01 | 大陸商齊魯製藥有限公司 | Parp7抑制劑的製備方法 |
| WO2024149234A1 (en) * | 2023-01-10 | 2024-07-18 | Angel Pharmaceutical Co., Ltd. | Parp7 inhibitors and uses thereof |
| WO2024149231A1 (en) * | 2023-01-10 | 2024-07-18 | Angel Pharmaceutical Co., Ltd. | Parp7 inhibitors and uses thereof |
| CN118388414A (zh) * | 2023-01-17 | 2024-07-26 | 中国药科大学 | 哒嗪酮类化合物及其制备方法、药物组合物和应用 |
| IL326495A (en) * | 2023-08-17 | 2026-04-01 | Kangbaida Sichuan Biotechnology Co Ltd | Pharmaceutical preparation of piperazine derivative, preparation method therefor, and use thereof |
| CN117126136B (zh) * | 2023-08-25 | 2026-05-19 | 安润医药科技（苏州）有限公司 | Parp7抑制剂及其应用 |
| CN121752568A (zh) * | 2023-08-29 | 2026-03-27 | 康百达（四川）生物医药科技有限公司 | 一种哌嗪衍生物的制备工艺及其中间体 |
| CN122438843A (zh) * | 2023-10-26 | 2026-07-21 | 奇树医药公司 | 作为parp7抑制剂的化合物 |
| CN122249234A (zh) * | 2023-11-13 | 2026-06-19 | 康百达（四川）生物医药科技有限公司 | 一种parp7抑制剂联合用药的药物组合及其治疗肿瘤的用途 |
| CN117342983B (zh) * | 2023-12-05 | 2024-02-06 | 康羽生命科学技术(苏州)有限公司 | 过乙酰化GalNAc-L96合成方法 |
| WO2025209574A1 (zh) * | 2024-04-03 | 2025-10-09 | 康百达（四川）生物医药科技有限公司 | 用于预防或治疗肿瘤的parp7抑制剂 |
| CN119684268B (zh) * | 2024-12-19 | 2026-04-03 | 诺沃斯达药业(上海)有限公司 | 一种parp7抑制剂的草酸共晶物及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110040A (en) * | 1993-06-29 | 2000-07-16 | Nissan Chemical Ind Ltd | Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them |
| JP3255293B2 (ja) | 1997-09-05 | 2002-02-12 | 松下電器産業株式会社 | 蛍光偏光法 |
| WO2002082082A2 (en) | 2001-04-09 | 2002-10-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorescence polarization assay |
| HU227237B1 (en) * | 2001-09-27 | 2010-12-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them |
| GB0301628D0 (en) | 2002-09-19 | 2003-02-26 | Aventis Pharma Inc | Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP) |
| CA2568835C (en) * | 2004-06-30 | 2014-05-27 | Janssen Pharmaceutica N.V. | Quinazolinone derivatives as parp inhibitors |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| EP2502918B1 (en) | 2006-07-25 | 2015-03-25 | Cephalon, Inc. | Pyridazinone Derivatives |
| JP5758630B2 (ja) * | 2007-11-15 | 2015-08-05 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Ｐａｒｐ阻害剤としてのピリダジノン誘導体 |
| DK2271626T3 (en) * | 2008-03-27 | 2015-02-23 | Janssen Pharmaceutica Nv | TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN |
| NZ623069A (en) * | 2009-08-17 | 2015-11-27 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| EP2970289A1 (en) * | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2016116602A1 (en) * | 2015-01-23 | 2016-07-28 | Astrazeneca Ab | Treatment of cancer |
| CN106749261A (zh) * | 2015-11-23 | 2017-05-31 | 中国科学院上海药物研究所 | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 |
| TWI785022B (zh) | 2017-03-28 | 2022-12-01 | 美商富曼西公司 | 新穎噠嗪酮類除草劑 |
| US12435078B2 (en) * | 2017-09-18 | 2025-10-07 | Gfb (Abc), Llc | Pyridazinones and methods of use thereof |
| GB201717080D0 (en) | 2017-10-18 | 2017-11-29 | Syngenta Participations Ag | Chemical process |
| US11293927B2 (en) | 2018-04-30 | 2022-04-05 | Ribon Therapeutics, Inc. | Screening methods for PARP modulators |
| BR112020022006A2 (pt) | 2018-04-30 | 2021-01-26 | Ribon Therapeutics Inc. | piridazinonas como inibidores de parp7 |
| WO2020223229A1 (en) | 2019-04-29 | 2020-11-05 | Ribon Therapeutics, Inc. | Solid forms of a parp7 inhibitor |
| WO2021087018A1 (en) | 2019-10-30 | 2021-05-06 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| TWI902715B (zh) | 2019-10-30 | 2025-11-01 | 美商律幫治療股份有限公司 | 作為ｐａｒｐ７抑制劑的嗒酮 |
-
2019
- 2019-04-29 BR BR112020022006-0A patent/BR112020022006A2/pt unknown
- 2019-04-29 MA MA52486A patent/MA52486B1/fr unknown
- 2019-04-29 IL IL278116A patent/IL278116B2/en unknown
- 2019-04-29 EA EA202092590A patent/EA202092590A1/ru unknown
- 2019-04-29 AR ARP190101124A patent/AR121419A1/es active IP Right Grant
- 2019-04-29 WO PCT/US2019/029582 patent/WO2019212937A1/en not_active Ceased
- 2019-04-29 ES ES19723272T patent/ES2949538T3/es active Active
- 2019-04-29 IL IL308983A patent/IL308983B2/en unknown
- 2019-04-29 MX MX2020011465A patent/MX2020011465A/es unknown
- 2019-04-29 FI FIEP19723272.1T patent/FI3788040T3/fi active
- 2019-04-29 CA CA3098585A patent/CA3098585A1/en active Pending
- 2019-04-29 SM SM20230172T patent/SMT202300172T1/it unknown
- 2019-04-29 RS RS20230450A patent/RS64283B1/sr unknown
- 2019-04-29 PT PT197232721T patent/PT3788040T/pt unknown
- 2019-04-29 DK DK19723272.1T patent/DK3788040T3/da active
- 2019-04-29 EP EP19723272.1A patent/EP3788040B1/en active Active
- 2019-04-29 CR CR20200518A patent/CR20200518A/es unknown
- 2019-04-29 PL PL19723272.1T patent/PL3788040T3/pl unknown
- 2019-04-29 AU AU2019262927A patent/AU2019262927B2/en active Active
- 2019-04-29 HU HUE19723272A patent/HUE062096T2/hu unknown
- 2019-04-29 CN CN202510769671.2A patent/CN120987912A/zh active Pending
- 2019-04-29 EP EP23161423.1A patent/EP4234551B1/en active Active
- 2019-04-29 KR KR1020207034323A patent/KR102862474B1/ko active Active
- 2019-04-29 TW TW108114978A patent/TWI811353B/zh active
- 2019-04-29 TW TW112127538A patent/TWI877697B/zh active
- 2019-04-29 PE PE2020001749A patent/PE20211382A1/es unknown
- 2019-04-29 LT LTEPPCT/US2019/029582T patent/LT3788040T/lt unknown
- 2019-04-29 SI SI201930544T patent/SI3788040T1/sl unknown
- 2019-04-29 MD MDE20210210T patent/MD3788040T2/ro unknown
- 2019-04-29 JP JP2020560916A patent/JP6942896B2/ja active Active
- 2019-04-29 HR HRP20230458TT patent/HRP20230458T1/hr unknown
- 2019-04-29 SG SG11202010183XA patent/SG11202010183XA/en unknown
- 2019-04-29 CN CN201980044076.5A patent/CN112424188B/zh active Active
- 2019-04-29 US US16/397,103 patent/US10550105B2/en active Active
- 2019-10-24 US US16/662,409 patent/US10870641B2/en active Active
-
2020
- 2020-08-11 US US16/990,677 patent/US11014913B2/en active Active
- 2020-10-21 ZA ZA2020/06549A patent/ZA202006549B/en unknown
- 2020-10-22 PH PH12020551760A patent/PH12020551760A1/en unknown
- 2020-10-29 CL CL2020002821A patent/CL2020002821A1/es unknown
- 2020-10-29 MX MX2023005804A patent/MX2023005804A/es unknown
- 2020-10-29 CO CONC2020/0013599A patent/CO2020013599A2/es unknown
- 2020-10-29 EC ECSENADI202069404A patent/ECSP20069404A/es unknown
-
2021
- 2021-04-12 US US17/227,705 patent/US11566020B1/en active Active
- 2021-09-08 JP JP2021145986A patent/JP7518049B2/ja active Active
-
2022
- 2022-10-27 US US17/974,830 patent/US20230192664A1/en not_active Abandoned
-
2023
- 2023-07-03 CY CY20231100310T patent/CY1126132T1/el unknown
-
2024
- 2024-01-30 AU AU2024200566A patent/AU2024200566B2/en active Active
- 2024-03-22 US US18/613,601 patent/US20250034120A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100861486B1 (ko) | 퀴나졸린 유도체 | |
| US12351582B2 (en) | Aurora kinase inhibitors and uses thereof | |
| JPWO2002066445A6 (ja) | キナゾリン誘導体 | |
| FI90980B (fi) | Menetelmä N-heterosyklisten N-(4-piperidyyli)-amidien valmistamiseksi | |
| JP2016053042A5 (enExample) | ||
| JP2013139459A (ja) | 化学化合物 | |
| CA2802130A1 (en) | Cyanoquinoline derivatives | |
| JP2023036991A (ja) | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法 | |
| EP3997086B1 (en) | Tetrahydroisoquinoline compounds | |
| JP2015518011A (ja) | ピロロ［２，１−ｆ］［１，２，４］トリアジン誘導体およびその抗腫瘍用途 | |
| US11548900B2 (en) | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | |
| TWI343375B (en) | Indolinone derivatives, substituted in the 6-position, their preparation and their use as medicaments | |
| PL186851B1 (pl) | Pochodne piperazynodionu jako środki farmaceutyczne | |
| CN108883099A (zh) | 噻唑烷酮化合物及其用途 | |
| JP2007502308A (ja) | 置換チオフェンとその使用 | |
| JP2026505122A (ja) | 新規化合物およびこれを含む薬学組成物 | |
| JP3223193B2 (ja) | インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質 | |
| CN101171236A (zh) | 抗肿瘤的四氢嘧啶 | |
| RU2822464C2 (ru) | Ингибиторы аврора-киназы и их применение | |
| CN121735914A (zh) | 一种用于进行癌症免疫治疗的parp7抑制剂 | |
| CN103554091B (zh) | 喹唑啉衍生物及其制备方法和用途 | |
| CN118974021A (zh) | 硫代苯并咪唑衍生物制备方法及用于其的新型中间体 | |
| KR20120047342A (ko) | 이마티닙의 신규 합성 방법 |